2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 252-254
Access, Representation, Population Health, Treatment Considerations, Biological Therapies, Immunotherapy, Adverse Events, Biological Processes, Immune Mechanism, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bleeding and Clotting, Thromboembolism, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Research, Clinical Research, Real-World Evidence, Study Population, Human, Adult
PAPER

1082 Commercialization of gene therapy for sickle cell disease: The phenotype of real-world referrals.

Aminatta Mitchell, DO, Nidhi Sharma, MS, Ph.D2, Marcos De lima, MD3, Hemalatha Geetharani Rangarajan I, MD4, Roberta C. G. Azbell, MD5
1 The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
2 The Ohio State University James Comprehensive Cancer Center, Columbus, Ohio, United States
3 The Ohio State University James Comprehensive Cancer Center, Columbus, Ohio, United States
4 Nationwide Children's Hospital, Columbus, Ohio, United States
5 The Ohio State University James Comprehensive Cancer Center, Columbus, Ohio, United States

Background: Sickle cell disease (SCD) is a red blood cell disorder in which a β-globin gene mutation leads to structurally abnormal hemoglobin. Vaso-occlusive events (VOEs) are a hallmark of SCD and lead to severe pain, organ damage and shortened lifespan. While disease-modifying therapies (DMTs) and transfusions are mainstays of therapy, the Food & Drug Administration (FDA) approval of exagamglogene autotemcel and lovotibeglogene autotemcel for people living with SCD (pwSCD) in 2023 provided a potentially functionally-curative option. However, the FDA indications are significantly broader than the trials’ inclusion criteria. This study thus describes the real-world phenotype of gene therapy (GT) referrals for pwSCD.  

Methods: We conducted an IRB-approved, single-center, retrospective study of all adult pwSCD referred to The James Transplant/Cell Therapy (BMT/CT) group between 12/9/2023-12/31/2024. We hypothesized that patients’ comorbidities would be the most cited reason for denial of GT. Descriptive statistics were performed on all data.   

Results: Twelve pwSCD met the inclusion criteria. At time of referral, median age was 38 years (r=24-60) and majority (58%) were female. All patients had SS/Sβ0, and majority (75%) were African American/Black. All patients were on either DMT (92%) or chronic transfusions (8%). The most common comorbidities were pulmonary (67%), ophthalmic, cardiac, orthopedic and alloimmunization (58% each) and venothromboembolic (VTE) (50%). Median VOEs averaged over the 2 years prior to referral was 2 (r=0-5).  

Over half of referrals came from internal (58%) versus external hematologists (42%). Except for the 2 patients (17%) who deferred prior to completing a consultation, median time from referral to consultation was 8 weeks (r=2-33 weeks).  Of the10 patients that completed a consultation, 7 (70%) proceeded to workup and 4 (40%) were deemed eligible to proceed to mobilization/collection. Reasons cited for ineligibility included heart failure (HF), age/stroke history, and psychosocial/caregiver concerns. Reasons cited for patient deferral included cost of traveling and not perceiving disease to be severe enough. 

Treatment duration (TD) was calculated for all patients that completed at least 1 consultation and was defined as time from date of referral to either date of patient deferral, patient ineligibility assessment, or GT infusion. At time of analysis, 2 (20%) of these patients were still in ongoing treatment. Of the remaining 8, median TD was ~7 months (r=1-840 days). For patients who either deferred or were deemed ineligible, median TD was ~5 months (r=1-387 days).  

Two of the 4 patients (50%) who proceeded to mobilization/collection have completed GT infusion, with total TDs of 7 and 21 months. The remaining 2 patients have been in ongoing treatment for 16 and 28 months. Patients had both mobilization/collection (50%), and manufacturing delays (75%). Mobilization/collection delays included postponed cycles due to acute VTE, acute infection causing VOE. Manufacturing delays included dose failure, partial dose, and dose contamination.  

Discussion: We herein describe real-world referrals received in the year following GT commercialization. With an outpatient adult SCD population of 350-400 patients, our BMT/CT program initially received ~1 referral/month in the first year. Median age was notably higher than one of the therapies’ trial age cut-off.  Genotype distribution did not include any non-SS/-Sβ0 patients despite the lack of commercial contraindication. Comorbidities at time of referral included presence of end-organ damage such as HF. A striking finding of this analysis was the TD, with a median TD for even consultation with and without workup being ~5 months. For patients proceeding to therapy, we found the process to be potentially years-long.   

Despite the small sample size limitation, this is the first study to our knowledge to describe real-world TD for pwSCD seeking GT. While we hypothesized that comorbidities would limit most adult pwSCD’s access to GT, we found that the majority were due to patient deferral. This perhaps highlights the daunting TD, and further studies are needed to address the impact that psychosocial and socioeconomic factors have on this outcome. Ongoing real-world analyses in this area are therefore critical, as we continue to refine real-world patient eligibility, improve multidisciplinary collaboration, and most importantly, counsel patients. 

Aminatta Mitchell, DO: No relevant conflicts of interest to declare.